FiltersReset Filters

With box warnings

Without box warnings

Branded

Generic

4 results

imdelltra
(Tarlatamab-dlle)
Amgen Inc
Usage: IMDELLTRA is indicated for treating adult patients with extensive stage small cell lung cancer (ES-SCLC) who have disease progression after platinum-based chemotherapy. Its approval is based on overall response rate and duration, with continued approval dependent on confirming clinical benefit in further studies.
imfinzi
(Durvalumab)
AstraZeneca Pharmaceuticals LP
Usage: IMFINZI is indicated for various cancers, including resectable non-small cell lung cancer (NSCLC), unresectable Stage III NSCLC, small cell lung cancer (SCLC), biliary tract cancer, hepatocellular carcinoma, advanced or recurrent endometrial cancer, and muscle invasive bladder cancer in combination with other treatments.
tecentriq
(atezolizumab)
Genentech, Inc.
Usage: TECENTRIQ is indicated for treating various cancers, including: non-small cell lung cancer (adjuvant and metastatic), extensive-stage small cell lung cancer, unresectable or metastatic hepatocellular carcinoma, BRAF V600 mutation-positive melanoma, and unresectable or metastatic alveolar soft part sarcoma.
tecentriq hybreza
(atezolizumab and hyaluronidase-tqjs)
Genentech, Inc.
Usage: TECENTRIQ HYBREZA is indicated for treating various cancers, including non-small cell lung cancer (NSCLC), small cell lung cancer (ES-SCLC), unresectable or metastatic hepatocellular carcinoma (HCC), BRAF V600 mutation-positive melanoma, and unresectable or metastatic alveolar soft part sarcoma (ASPS) in adults.

Medications for Small Cell Lung Cancer Extensive Stage

imdelltra

imfinzi

tecentriq

tecentriq hybreza